SuperSmart← Back to DiscoverDiscover
What this page shows
Baxter's sale announcement framed Vantive as a divested kidney-care business. Its first-quarter 2025 filing describes continuing reciprocal product and fulfillment arrangements for up to ten years, with extension and early-exit provisions.
This creates a more useful question than who owns the company: which supposedly diversified purchases still depend on the same manufacturer or components? Separate ownership and continuing supply relationships must both be considered. The contract establishes interdependence; it does not establish that any particular pair of products shares a plant. Product schedules and facility mappings are the next evidence needed.
Recorded evidence
Limitations & review notes
- Research draft. Conclusions may change; review the sources and limitations before relying on them.
- Restored archival research draft: not independently reverified for this republication and not actively monitored. Check the linked originals and dated scope before relying on it.
- Separate ownership does not prove independent supply, but this agreement alone also does not prove a common single point of failure.
- The up-to-ten-year term includes extension and early-exit provisions; it is not a fixed ten-year dependency for every product.
- The agreement was already publicly disclosed. Facility-level dependencies remain an open question, not an established finding.